JPWO2021127525A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021127525A5 JPWO2021127525A5 JP2022538201A JP2022538201A JPWO2021127525A5 JP WO2021127525 A5 JPWO2021127525 A5 JP WO2021127525A5 JP 2022538201 A JP2022538201 A JP 2022538201A JP 2022538201 A JP2022538201 A JP 2022538201A JP WO2021127525 A5 JPWO2021127525 A5 JP WO2021127525A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 103
- 238000009472 formulation Methods 0.000 claims description 93
- 238000001990 intravenous administration Methods 0.000 claims description 60
- 239000000427 antigen Substances 0.000 claims description 39
- 102000036639 antigens Human genes 0.000 claims description 39
- 108091007433 antigens Proteins 0.000 claims description 39
- 239000012634 fragment Substances 0.000 claims description 39
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 31
- 229960002885 histidine Drugs 0.000 claims description 31
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 14
- 229930006000 Sucrose Natural products 0.000 claims description 14
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 14
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 14
- 229940068977 polysorbate 20 Drugs 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- 238000001356 surgical procedure Methods 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 230000009424 thromboembolic effect Effects 0.000 claims description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 150000002016 disaccharides Chemical class 0.000 claims description 8
- 150000002411 histidines Chemical class 0.000 claims description 8
- 229920000136 polysorbate Polymers 0.000 claims description 8
- 229950008882 polysorbate Drugs 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 150000005846 sugar alcohols Chemical class 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 206010003662 Atrial flutter Diseases 0.000 claims description 6
- 206010014522 Embolism venous Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 208000004043 venous thromboembolism Diseases 0.000 claims description 6
- 108010080805 Factor XIa Proteins 0.000 claims description 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 208000005189 Embolism Diseases 0.000 claims description 4
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 claims description 4
- -1 histidine HCl monohydrate Chemical class 0.000 claims description 4
- 150000002772 monosaccharides Chemical group 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 125000000185 sucrose group Chemical group 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 3
- 239000000612 proton pump inhibitor Substances 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 2
- 206010014498 Embolic stroke Diseases 0.000 claims description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010051292 Protein S Deficiency Diseases 0.000 claims description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 238000012084 abdominal surgery Methods 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000000399 orthopedic effect Effects 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 210000000115 thoracic cavity Anatomy 0.000 claims description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 2
- 210000000629 knee joint Anatomy 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 2
- 229940071643 prefilled syringe Drugs 0.000 claims 2
- 238000009434 installation Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011541 total hip replacement Methods 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 description 71
- 238000000034 method Methods 0.000 description 37
- 108010074864 Factor XI Proteins 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000004023 fresh frozen plasma Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- 229940124135 Factor VIII inhibitor Drugs 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 108010052295 fibrin fragment D Proteins 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951887P | 2019-12-20 | 2019-12-20 | |
| US62/951,887 | 2019-12-20 | ||
| PCT/US2020/066151 WO2021127525A1 (fr) | 2019-12-20 | 2020-12-18 | Formulations pharmaceutiques et schémas posologiques pour anticorps de facteur xi/xia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023507795A JP2023507795A (ja) | 2023-02-27 |
| JPWO2021127525A5 true JPWO2021127525A5 (fr) | 2023-12-15 |
Family
ID=76478578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538201A Pending JP2023507795A (ja) | 2019-12-20 | 2020-12-18 | 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230071973A1 (fr) |
| EP (1) | EP4076511A4 (fr) |
| JP (1) | JP2023507795A (fr) |
| KR (1) | KR20220119090A (fr) |
| CN (1) | CN115003325A (fr) |
| BR (1) | BR112022012064A2 (fr) |
| CA (1) | CA3161118A1 (fr) |
| IL (1) | IL293367A (fr) |
| WO (1) | WO2021127525A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311801A (en) * | 2021-11-18 | 2024-05-01 | Anthos Therapeutics Inc | Dosage regimen of factor XI/XIA antibodies |
| WO2023131213A1 (fr) * | 2022-01-05 | 2023-07-13 | 上海迈晋生物医药科技有限公司 | Composition pharmaceutique comprenant un anticorps anti-fxi/fxia et son utilisation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090060453A (ko) * | 2006-09-25 | 2009-06-12 | 메디뮨 엘엘씨 | 안정화된 항체 제제 및 그것의 용도 |
| SG11201505330QA (en) * | 2013-02-08 | 2015-08-28 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
| JOP20200312A1 (ar) * | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| MX2018002166A (es) * | 2015-08-20 | 2018-09-12 | Abbvie Stemcentrx Llc | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. |
| WO2018116267A2 (fr) * | 2016-12-23 | 2018-06-28 | Novartis Ag | Méthodes de traitement avec des anticorps anti-facteur xi/xia |
| IL308980A (en) * | 2016-12-23 | 2024-01-01 | Novartis Ag | Antibodies against factor XI and methods of their use |
| RS62780B1 (sr) * | 2017-01-19 | 2022-01-31 | Bayer Pharma AG | Nova stabilna formulacija za fxia antitela |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| BR112020010016A2 (pt) * | 2017-11-22 | 2020-11-10 | Novartis Ag | agentes de ligação de reversão para anticorpos antifator xi/xia e usos dos mesmos |
| IL311801A (en) * | 2021-11-18 | 2024-05-01 | Anthos Therapeutics Inc | Dosage regimen of factor XI/XIA antibodies |
-
2020
- 2020-12-18 WO PCT/US2020/066151 patent/WO2021127525A1/fr active Application Filing
- 2020-12-18 CA CA3161118A patent/CA3161118A1/fr active Pending
- 2020-12-18 BR BR112022012064A patent/BR112022012064A2/pt unknown
- 2020-12-18 CN CN202080093971.9A patent/CN115003325A/zh active Pending
- 2020-12-18 IL IL293367A patent/IL293367A/en unknown
- 2020-12-18 EP EP20903182.2A patent/EP4076511A4/fr active Pending
- 2020-12-18 JP JP2022538201A patent/JP2023507795A/ja active Pending
- 2020-12-18 KR KR1020227024670A patent/KR20220119090A/ko unknown
- 2020-12-18 US US17/785,660 patent/US20230071973A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020142517A (ru) | Антитела к фактору xi и способы их применения | |
| US10202449B2 (en) | Cachexia treatment | |
| JP7145162B2 (ja) | 化膿性汗腺炎の処置 | |
| JP6460993B2 (ja) | 血管疾患及びその合併症の処置 | |
| IL275350A (en) | Treatment of neoplastic diseases | |
| EP3554543A2 (fr) | Composition aqueuse stable d'anticorps anti-c5 | |
| JP2022540781A (ja) | 抗ｃｄ４７／ｐｄ‐ｌ１二重特異性抗体を含む製剤、その調製方法及び使用 | |
| BR112021008778A2 (pt) | Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn | |
| WO2019020069A1 (fr) | Composition pharmaceutique d'anticorps sost et utilisations de celle-ci | |
| CN113194821A (zh) | 逆转替卡格雷活性的方法 | |
| AU2018361975A1 (en) | Method of treating tendinopathy using interleukin-17 (IL-17) antagonists | |
| JPWO2021127525A5 (fr) | ||
| RU2745814C1 (ru) | Водная фармацевтическая композиция левилимаба и ее применение | |
| US11267898B2 (en) | Anti-PODXL antibody MAI1738 and its use for cancer treatment | |
| BR112021004900A2 (pt) | anticorpos de quimiocina pan-elr+ cxc para o tratamento de hidradenitis suppurativa | |
| CN116688115B (zh) | 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途 | |
| CN113993543B (zh) | 使用抗cd38抗体的组合疗法 | |
| RU2790561C2 (ru) | Соединение, связывающее адреномедуллин (adm), для применения для терапии или профилактики симптомов заболевания | |
| US20240228600A1 (en) | Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina | |
| CN116172947A (zh) | 一种含特异性结合vegf和ang2的双特异性抗体的药物组合物 | |
| TW202417482A (zh) | 治療補體介導疾病的方法 | |
| TW202045537A (zh) | 化膿性汗腺炎的治療 | |
| CN116490520A (zh) | 用于covid-19肺炎的托珠单抗和瑞德西韦组合疗法 | |
| WO2022212645A1 (fr) | Réduction de l'hémolyse associée à une chirurgie chez des patients atteints de la maladie des agglutinines froides | |
| US20080254043A1 (en) | Drug For Treating Ischemic Disease |